Business UpdateJul 2, 2026, 05:07 PM
Iovance Updates Corporate Presentation; FY26 Revenue $350M-$370M
AI Summary
Iovance Biotherapeutics updated its corporate presentation on June 30, 2026, for use at healthcare conferences and with analysts and stockholders. The presentation provides a corporate overview, including financial guidance for Q2 2026 revenue of $86M-$88M and full-year 2026 revenue of $350M-$370M. It also highlights the commercial launch of Amtagvi, pipeline advancements, and manufacturing capabilities, projecting a cash runway into 2028.
Key Highlights
- Updated corporate presentation on June 30, 2026.
- Q2 2026 revenue guidance: $86M-$88M.
- Full Year 2026 revenue guidance: $350M-$370M.
- Cash position as of March 31, 2026: ~$319M, with runway into 2028.
- Amtagvi commercial launch: >90 authorized treatment centers.
- Manufacturing capacity: 5K+ patients/year for TIL cell therapies.
- Pipeline includes TILVANCE-301, IOV-LUN-202, IOV-SAR-201, IOV-END-201.
- Next-gen products: IOV-4001, IOV-3001, IOV-5001 in clinical development.
Price Impact
More from IOVA